162 related articles for article (PubMed ID: 17126079)
1. Link test--A statistical method for finding prostate cancer biomarkers.
Deng X; Geng H; Bastola DR; Ali HH
Comput Biol Chem; 2006 Dec; 30(6):425-33. PubMed ID: 17126079
[TBL] [Abstract][Full Text] [Related]
2. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
Yasui Y; Pepe M; Thompson ML; Adam BL; Wright GL; Qu Y; Potter JD; Winget M; Thornquist M; Feng Z
Biostatistics; 2003 Jul; 4(3):449-63. PubMed ID: 12925511
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery.
Tanase CP; Codrici E; Popescu ID; Mihai S; Enciu AM; Necula LG; Preda A; Ismail G; Albulescu R
Oncotarget; 2017 Mar; 8(11):18497-18512. PubMed ID: 28061466
[TBL] [Abstract][Full Text] [Related]
4. An integrative multi-platform analysis for discovering biomarkers of osteosarcoma.
Li G; Zhang W; Zeng H; Chen L; Wang W; Liu J; Zhang Z; Cai Z
BMC Cancer; 2009 May; 9():150. PubMed ID: 19445706
[TBL] [Abstract][Full Text] [Related]
5. [Proteomic analysis of prostate cancer using surface enhanced laser desorption/ionization mass spectrometry].
Pan YZ; Xiao XY; Zhao D; Zhang L; Ji GY; Li Y; He DC; Zhao XJ; Yang BX
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3172-5. PubMed ID: 16405834
[TBL] [Abstract][Full Text] [Related]
6. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.
McLerran D; Grizzle WE; Feng Z; Bigbee WL; Banez LL; Cazares LH; Chan DW; Diaz J; Izbicka E; Kagan J; Malehorn DE; Malik G; Oelschlager D; Partin A; Randolph T; Rosenzweig N; Srivastava S; Srivastava S; Thompson IM; Thornquist M; Troyer D; Yasui Y; Zhang Z; Zhu L; Semmes OJ
Clin Chem; 2008 Jan; 54(1):44-52. PubMed ID: 17981926
[TBL] [Abstract][Full Text] [Related]
7. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.
McLerran D; Grizzle WE; Feng Z; Thompson IM; Bigbee WL; Cazares LH; Chan DW; Dahlgren J; Diaz J; Kagan J; Lin DW; Malik G; Oelschlager D; Partin A; Randolph TW; Sokoll L; Srivastava S; Srivastava S; Thornquist M; Troyer D; Wright GL; Zhang Z; Zhu L; Semmes OJ
Clin Chem; 2008 Jan; 54(1):53-60. PubMed ID: 18024530
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer.
Malik G; Ward MD; Gupta SK; Trosset MW; Grizzle WE; Adam BL; Diaz JI; Semmes OJ
Clin Cancer Res; 2005 Feb; 11(3):1073-85. PubMed ID: 15709174
[TBL] [Abstract][Full Text] [Related]
9. Feature selection and nearest centroid classification for protein mass spectrometry.
Levner I
BMC Bioinformatics; 2005 Mar; 6():68. PubMed ID: 15788095
[TBL] [Abstract][Full Text] [Related]
10. Proteomics in diagnosis of prostate cancer.
Davalieva K; Polenakovic M
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):5-36. PubMed ID: 26076772
[TBL] [Abstract][Full Text] [Related]
11. The expression profile of phosphatidylinositol in high spatial resolution imaging mass spectrometry as a potential biomarker for prostate cancer.
Goto T; Terada N; Inoue T; Nakayama K; Okada Y; Yoshikawa T; Miyazaki Y; Uegaki M; Sumiyoshi S; Kobayashi T; Kamba T; Yoshimura K; Ogawa O
PLoS One; 2014; 9(2):e90242. PubMed ID: 24587297
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic potential of serum proteomic patterns in prostate cancer.
Bañez LL; Prasanna P; Sun L; Ali A; Zou Z; Adam BL; McLeod DG; Moul JW; Srivastava S
J Urol; 2003 Aug; 170(2 Pt 1):442-6. PubMed ID: 12853795
[TBL] [Abstract][Full Text] [Related]
13. SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression.
Malik G; Rojahn E; Ward MD; Gretzer MB; Partin AW; Semmes OJ; Veltri RW
Prostate; 2007 Oct; 67(14):1565-75. PubMed ID: 17705230
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer biomarker discovery using high performance mass spectral serum profiling.
Oh JH; Lotan Y; Gurnani P; Rosenblatt KP; Gao J
Comput Methods Programs Biomed; 2009 Oct; 96(1):33-41. PubMed ID: 19423179
[TBL] [Abstract][Full Text] [Related]
15. Molecular classification of liver cirrhosis in a rat model by proteomics and bioinformatics.
Xu XQ; Leow CK; Lu X; Zhang X; Liu JS; Wong WH; Asperger A; Deininger S; Eastwood Leung HC
Proteomics; 2004 Oct; 4(10):3235-45. PubMed ID: 15378689
[TBL] [Abstract][Full Text] [Related]
16. Reproducible cancer biomarker discovery in SELDI-TOF MS using different pre-processing algorithms.
Zou J; Hong G; Guo X; Zhang L; Yao C; Wang J; Guo Z
PLoS One; 2011; 6(10):e26294. PubMed ID: 22022591
[TBL] [Abstract][Full Text] [Related]
17. MALDI mass spectrometry in prostate cancer biomarker discovery.
Flatley B; Malone P; Cramer R
Biochim Biophys Acta; 2014 May; 1844(5):940-9. PubMed ID: 23831156
[TBL] [Abstract][Full Text] [Related]
18. Cross-platform method for identifying candidate network biomarkers for prostate cancer.
Jin G; Zhou X; Cui K; Zhang XS; Chen L; Wong ST
IET Syst Biol; 2009 Nov; 3(6):505-12. PubMed ID: 19947776
[TBL] [Abstract][Full Text] [Related]
19. Probabilistic disease classification of expression-dependent proteomic data from mass spectrometry of human serum.
Lilien RH; Farid H; Donald BR
J Comput Biol; 2003; 10(6):925-46. PubMed ID: 14980018
[TBL] [Abstract][Full Text] [Related]
20. The use of matrix coating assisted by an electric field (MCAEF) to enhance mass spectrometric imaging of human prostate cancer biomarkers.
Wang X; Han J; Hardie DB; Yang J; Borchers CH
J Mass Spectrom; 2016 Jan; 51(1):86-95. PubMed ID: 26757076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
